



ESTUDIOS Y RESULTADOS CLÍNICOS

Kranzler, H. R., Tennen, H., Armeli, S., Chan, G., Covault, J., Arias, A., & Oncken, C. (2009). Targeted naltrexone for problem drinkers. *Journal of Clinical Psychopharmacology*, 29(4), 350–357.

Heinälä, P., H. Alho, K. Kiianmaa, J. Lönnqvist, K. Kuoppasalmi, and J. D. Sinclair. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: A factorial double-blind placebo-controlled trial. *Journal of Clinical Psychopharmacology*.

Grant BF, Saha TD, Ruan WJ, et al. Epidemiology of DSM-5 Drug Use Disorder Results From the National Epidemiologic Survey on Alcohol and Related Conditions—III. *JAMA Psychiatry*. 2016;73(1):39–47.

Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for Adults With Alcohol Use Disorders in Outpatient Settings: A Systematic Review and Meta-analysis. *JAMA*. 2014; 311(18): 1889-1900.

Pettinati HM, Anton RF, Willenbring ML. The COMBINE Study—: An Overview of the Largest Pharmacotherapy Study to Date for Treating Alcohol Dependence. *Psychiatry (Edmont)*. 2006; 3(10): 36-39.

Foa EB, Yusko DA, McLean CP, et al. Concurrent Naltrexone and Prolonged Exposure Therapy for Patients With Comorbid Alcohol Dependence and PTSDA Randomized Clinical Trial. *JAMA*. 2013; 310(5):488–495.

Darren R. Quelch et al. Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study, *Biological Psychiatry* (2017).